Perspective Therapeutics, Inc. (CATX) - Dilution Analysis

10-Q filing | 103.6M shares outstanding

10-K filing | 113.9M shares outstanding

10-Q filing | 74.3M shares outstanding

10-Q filing | 74.2M shares outstanding

10-Q filing | 72.4M shares outstanding

POS AM filing: The filing is a POS AM for an offering of common stock, preferred stock, debt securities, warrants, or units up to an aggregate amount of $500,000,000, with a concurrent ATM offering of common stock up to $250,000,000.

POS AM filing: The company is filing a POS AM to register the offering of common stock, preferred stock, warrants, debt securities or units up to an aggregate amount of $500,000,000, and is also offering common stock at-the-market for up to $250,000,000.

10-K filing | 74.1M shares outstanding

10-Q filing | 70.6M shares outstanding

8-K filing: Perspective Therapeutics, Inc. entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC to offer and sell shares of its common stock having an aggregate sales price of up to $250,000,000 and terminated the At Market Issuance Sales Agreement, dated November 17, 2023, with Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC. ($49.9M proceeds)

10-Q filing | 66.6M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 622,629,038 → 67,400,000

8-K filing: Perspective Therapeutics, Inc. completed an underwritten offering of 51,515,880 shares of common stock and 1,464,252 pre-funded warrants at a price of $1.51 per share and $1.509 per warrant, respectively, resulting in gross proceeds of approximately $80 million. ($80.0M proceeds)

10-Q filing | 622.6M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 148,352,336 shares of common stock by selling stockholders.

10-K filing | 267.6M shares outstanding

8-K filing: Perspective Therapeutics, Inc. completed a private placement of 92,009,981 shares of common stock at a price of $0.95 per share, resulting in gross proceeds of approximately $87.4 million before deducting fees and expenses. ($87.4M proceeds)

8-K filing: Perspective Therapeutics, Inc. completed a public offering of 132,075,218 shares of common stock and pre-funded warrants to purchase 30,086,944 shares, along with a private placement of 56,342,355 shares to Lantheus Alpha Therapy, LLC. ($89.8M proceeds)

S-3/A filing: This S-3/A filing from 2023-12-07 relates to a shelf offering of common stock, preferred stock, warrants, and debt securities with an aggregate initial offering price not to exceed $200,000,000. The company intends to use the net proceeds from this offering for general corporate purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, working capital, capital expenditures, acquisitions of new technologies, products or businesses and investments.

S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, warrants and/or debt securities with an aggregate offering price not to exceed $200,000,000.

10-Q filing | 280.6M shares outstanding

10-Q filing | 280.0M shares outstanding

10-Q filing | 278.7M shares outstanding

10-Q filing | 142.1M shares outstanding

10-K filing | 142.0M shares outstanding

10-Q filing | 142.0M shares outstanding

10-Q filing | 142.0M shares outstanding

10-Q filing | 141.9M shares outstanding

10-K filing | 141.9M shares outstanding

10-Q filing | 141.5M shares outstanding

10-Q filing | 141.2M shares outstanding

10-Q filing | 87.2M shares outstanding

10-K filing | 68.9M shares outstanding

10-Q filing | 67.7M shares outstanding

10-Q filing | 67.7M shares outstanding

S-3 filing: Issuer may offer shares of common stock, preferred stock and/or warrants up to an aggregate amount of $80,000,000.